Soligenix corporate update letter - key highlights and upcoming catalysts

Princeton, n.j., jan. 10, 2022 /prnewswire/ -- soligenix, inc. (nasdaq: sngx) (soligenix or the company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, today issued an update letter from its president and chief executive officer, dr. christopher j.

SNGX Ratings Summary

SNGX Quant Ranking